Dian Diagnostics Group Co. Ltd.

Dian Diagnostics Group Co. has seen a notable rise in its stock, achieving an intraday high and significant monthly growth, contrasting with a decline in the broader market. The company reported strong financial metrics, including impressive operating cash flow and reduced raw material costs, reinforcing its position in the pharmaceuticals sector.

Dian Diagnostics Group Co. has shown strong stock performance, with a notable increase on July 1, 2026. The company has outperformed the Shanghai Composite both weekly and year-to-date, reporting significant growth in operating profit and a substantial rise in overall profits. Its market capitalization stands at CNY 7,381 million.

Dian Diagnostics Group Co. has experienced a recent evaluation adjustment, highlighting shifts in its financial metrics and market position. Key indicators include a Price to Book Value of 1.95, a negative P/E ratio, and an EV to EBITDA ratio of 38.51, reflecting its operational performance and revenue generation capabilities.

Dian Diagnostics Group Co. faced a notable decline in its stock price, contrasting with broader market trends. The company reported a significant drop in net sales and has experienced negative results for nine consecutive quarters, resulting in a negative return on equity. Its market capitalization is CNY 10,955 million.

Dian Diagnostics Group Co. faced a notable decline in stock performance, with significant drops over the past week and month. The company has reported negative financial results for nine consecutive quarters, including declines in net sales and profit, raising concerns about its profitability and market position.

Dian Diagnostics Group Co. faced notable stock declines on March 3, 2026, contrasting with the broader market's performance. Over the past month, the company has seen a significant downturn, with financial metrics indicating challenges, including a sharp drop in net profit and a negative return on capital employed.

Dian Diagnostics Group Co. faced notable stock activity on February 24, 2026, with a significant decline amid broader market trends. The company reported a sharp drop in net profit and low return on capital employed, highlighting operational challenges. Its long-term performance shows concerning declines over three and five years.